Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05573074 · ClinicalTrials.gov registry record · NA

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

A NA study of Major Depressive Disorder, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
3
Study locations

NCT05573074: Recruiting NA study of Major Depressive Disorder, sponsored by NYU Langone Health.

NCT05573074 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 120 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05573074, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.

Primary Outcome

Cerebral blood flow (CBF) is measured as Blood oxygen Level Dependent (BOLD) signal on functional magnetic resonance imaging (fMRI). BOLD signal reflect changes in regional cerebral blood flow that delineates regional activity, A positive BOLD signal marks an increase in regional blood flow while a negative BOLD signal marks a decrease in regional blood flow. A positive percent change indicates that blood flow increased in the region of interest between scans, a negative percent change indicates

Conditions Studied

Interventions

  • DEVICE Sham
  • DEVICE Transcranial Photobiomodulator

Study Locations (3)

New York

  • NYU Langone Health - New York
  • Nathan Kline Institute for Psychiatric Research - Orangeburg

Massachusetts

  • Harvard Medical School - Boston

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-04-01
Est. Completion 2026-06-30
Phase NA
NYU Langone Health

1,164 total trials

What NCT05573074 shows while recruiting

NCT05573074 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower).

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.

NCT05573074 reports a single indexed study location in New York, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05573074 about?

NCT05573074 is a clinical study titled "Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33". The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.

What is the current status of trial NCT05573074?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-04-01. Estimated completion is 2026-06-30.

What conditions does trial NCT05573074 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT05573074?

The interventions under investigation include: Sham (DEVICE), Transcranial Photobiomodulator (DEVICE).

Who is sponsoring clinical trial NCT05573074?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05573074 being conducted?

This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05573074's enrollment target sits among peer trials

120 117th of 282 higher than 160 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05573074, the US trial registry maintained by the National Library of Medicine. NCT05573074 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.